Table 5.

Association between Specific EBV Genotypes and Tumor Features

Tumor characteristics	A/B genotypes No. (%) (n=52)				D/C subtypes No. (%) (n=45)
	No. (%) of cases	Genotype- A	Genotype- B	P-value	Total No. (%) of cases	Subtype-D	Subtype-C	P-value
Tumor size				0.4				0.6
less than 2 cm	4 (7.7)	4/4 (100)	0		3 (6.7)	3/3 (100)	0
more than 2 cm	48 (92.3)	43/48 (89.6)	5/48 (10.4)		42 (93.3)	40/42 (95.2)	2/42 (4.8)
Tumor stage				0.2				0.4
stage 1	3 (5.8)	3/3 (100)	0		3 (6.7)	3/3 (100)	0
stage 2	16 (30.8)	16/16 (100)	0		15 (33.3)	15/15 (100)	0
stage 3	33 (63.5)	28/33 (84.8)	5/33 (15.2)		27 (60)	25/27 (92.6)	2/27 (7.4)
Tumor grade				0.5				0.04
Grade 1	5 (9.6)	5/5 (100)	0
Grade 2	17 (32.7)	16/17 (94.1)	1/17 (5.9)		15 (33.3)	13/15 (86.7)	2/15 (13.3)
Grade 3	30 (57.7)	26/30 (86.7)	4/30 (13.3)		30 (66.7)	30/30 (100)	0
Tumor Histology				0.7				-
IDC	51 (98.1)	46/51 (90.2)	5/51 (9.8)		45 (100)	43/45 (95.6)	2/45 (4.4)
ILC	1 (1.9)	1/1 (100)	0		0	0	0
Metastasis				0.8				0.4
No	43 (82.7)	39/43 (90.7)	4/43 (9.3)		36 (80)	34/36 (94.4)	2/36 (5.6)
Yes	9 (17.3)	8/9 (88.9)	1/9 (11.1)		9 (20)	9/9 (100)	0
ER				0.6				0.07
Negative	26 (50)	23/26 (88.5)	3/26 (11.5)		27 (60)	27/27 (100)	0
Positive	26 (10)	24/26 (92.3)	2/26 (7.7)		18 (40)	16/18 (88.9)	2/18 (11.1)
PR				0.8				0.04
Negative	29 (55.8)	26/29 (89.7)	3/29 (10.3)		30 (66.7)	30/30 (100)	0
Positive	23 (44.2)	21/23 (91.3)	2/23 (8.7)		15 (33.3)	13/15 (86.7)	2/15 (13.3)
HER2				0.7				0.01
Negative	18 (34.6)	16/18 (88.9)	2/18 (11.1)		12 (26.7)	10/12 (83.3)	2/12 (16.7)
Positive	34 (65.4)	31/34 (91.2)	3/34 (8.8)		33 (73.3)	33/33 (100)	0

IDC, Infiltrating ductal carcinoma; ILC, Invasive lobular carcinoma; PR, Progesterone receptor; ER, Estrogen receptor; HER2, Human epidermal growth